Head-to-head · Cost-Efficiency Index
Edessa vs Claya
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Edessa
A six-month committer, or someone willing to click past the front page to the table with the real monthly rate.
Visit EdessaClaya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaThe verdict
Edessa takes it, leading the Cost-Efficiency Index 70 to 69. Clean three-rung tables one click in, behind a front page whose three cards all quote six-month rungs and whose cheapest belongs to a different drug. Claya still earns a C — Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Edessa.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Edessa | Claya |
|---|---|---|
| Cost-Efficiency Index | 70/100 | 69/100 |
| Semaglutide / mo | $179/mo month-to-month for the injection; $160 on three months and $135 on six | $149/mo (all doses, compounded) |
| Tirzepatide / mo | $239/mo month-to-month; $219 on three months and $209 on six | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $2,148 | $1,788 |
| Tirzepatide / yr (modeled) | $2,868 | $2,388 |
| Coverage | Not disclosed | Coverage not published |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #91 | #97 |
Edessa
70/100Where the value is
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
The tradeoffs
- The front page leads with "Start for just $135", a six-month prepay on the semaglutide injection
- All three front-page cards quote the six-month rung, so the real monthly rates appear only after a click
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.